02:13:59 EDT Tue 16 Jul 2024
Enter Symbol
or Name
USA
CA



Q:NKTX - NKARTA INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NKTX - Q0.16.43·7.164.37.02+0.517.8972.56,4125,3596.56  7.24  6.5316.24  1.2819:57:30Jun 2715 min RT 2¢

Recent Trades - Last 10 of 5359
Time ETExPriceChangeVolume
19:57:30Q7.15840.64841
19:38:19Q7.160.651
19:37:55Q7.160.654
18:54:19Q7.160.652
16:06:41Q7.020.515,854
16:02:17Q7.020.51196
16:02:15Q7.020.51320
16:02:11Q7.020.51237
16:01:51Q7.020.514,140
16:00:07Q7.020.511,957

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-06-27 06:00U:NKTXNews ReleaseNkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
2024-06-13 16:01U:NKTXNews ReleaseNkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
2024-05-09 16:01U:NKTXNews ReleaseNkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
2024-04-03 16:02U:NKTXNews ReleaseNkarta to Participate in Upcoming Investor Conferences
2024-03-25 06:30U:NKTXNews ReleaseNkarta Announces Pricing of $240 Million Underwritten Offering
2024-03-21 16:01U:NKTXNews ReleaseNkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
2024-02-28 08:01U:NKTXNews ReleaseNkarta to Participate in Upcoming Investor Conferences
2024-01-09 10:25U:NKTXNews ReleaseGlobal Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
2023-12-09 20:31U:NKTXNews ReleaseNkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
2023-11-09 16:02U:NKTXNews ReleaseNkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
2023-11-07 08:02U:NKTXNews ReleaseNkarta to Participate at Upcoming Investor Conferences
2023-10-17 11:47U:NKTXNews ReleaseLupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis
2023-10-17 07:01U:NKTXNews ReleaseNkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
2023-10-16 16:01U:NKTXNews ReleaseNkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
2023-08-10 07:01U:NKTXNews ReleaseNkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
2023-08-03 08:02U:NKTXNews ReleaseNkarta to Participate at Upcoming Investor Conference